ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ BỆNH VIÊM GAN C MẠN TÍNH PHÁC ĐỒ SOFOSBUVIR/DACLATASVIR Ở BỆNH NHÂN ĐỒNG NHIỄM HCV/HIV

Abstract

Objective: To evaluate the treatment effects of Sofosbuvir / Dalatasvir regimen in HIV patients with chronic HCV infection at Dong Da General Hospital, Hanoi.

Objects and methods: Descriptive and prospective studies on 60 HCV / HIV co-infected subjects receiving Sofosbuvir / Daclatasvir regimen from June 2018 to May 2020.

Result: 100% of patients with clinical stage 1, clinical symptoms and opportunistic infections changed significantly after 4 weeks of treatment, 100% of follow-up patients had no clinical manifestations and opportunistic infections at T4 and stabilization later. Mean CD4 cell count at the end of follow-up increased significantly with the start of treatment (p <0.01). HIV-RNA load at the end of follow-up of cirrhosis and hepatitis 100% group reached levels below detection threshold. The sustained viral response after 12 weeks of treatment (SVR 12) of both groups was 100%. The mean value of liver enzymes after treatment decreased compared to the time of T0 (p <0.01); and 100% of patients had normal liver enzymes at time of SVR12. APRI index decreased significantly compared to the time of T0 (p <0.01); based on Fibroscan results, the rate of hepatitis and cirrhosis is unchanged.